Alzheimer's disease

Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen
Reuters
Tue, 09/26/23 - 10:23 am
Biogen
Eisai
Japan
Leqembi
Alzheimer's disease
Cassava Sciences Announces Positive Interim Safety Review of Simufilam On-going Phase 3 Trials in Patients with Alzheimer’s Disease
BioSpace
Mon, 09/18/23 - 07:45 pm
Cassava Sciences
clinical trials
Simulfilam
Alzheimer's disease
Anavex’s Blarcamesine Slows Cognitive Decline in Alzheimer’s Patients
BioSpace
Fri, 09/15/23 - 11:41 am
Anavex
Alzheimer's disease
blarcamesine
clinical trials
The Alzheimer’s Treatment Landscape: Leqembi vs. Donanemab
BioSpace
Mon, 09/11/23 - 12:34 pm
Alzheimer's disease
Eli Lilly
Biogen
Eisai
Leqembi
donanemab
Competing in These 3 Markets Could Send Eli Lilly Stock Soaring
Motley Fool
Tue, 09/5/23 - 11:23 am
Eli Lilly
Alzheimer's disease
obesity
painkillers
Vaxxinity Alzheimer’s treatment shows promising results in early trial
Biopharma Reporter
Tue, 08/15/23 - 10:07 am
Vaxxinity
clinical trials
UB-311
Alzheimer's disease
New Alzheimer’s drug raises hopes — along with questions
Medical Marketing and Media
Mon, 08/14/23 - 06:54 pm
FDA
Alzheimer's disease
Eisai
Biogen
Leqembi
More Alzheimer's Treatments Are Coming: This Company Can Help With Early Detection
Motley Fool
Thu, 08/10/23 - 11:39 am
Alzheimer's disease
diagnostics
Quest Diagnostics
Takeda, Denali drop Alzheimer's asset after phase 1 peak reveals 'narrow therapeutic window'
Fierce Biotech
Wed, 08/9/23 - 11:56 am
Takeda
Denali Therapeutics
Alzheimer's disease
clinical trials
The real costs of the new Alzheimer’s drug, most of which will fall to taxpayers
Medical Marketing and Media
Wed, 08/2/23 - 10:43 pm
Eisai
Biogen
Leqembi
Alzheimer's disease
Headband to treat mild and moderate Alzheimer’s disease to be trialled
Clinical Trials Arena
Tue, 08/1/23 - 11:48 am
Alzheimer's disease
Medtech
clinical trials
Electro Cellular Healthcare Solutions
Promising new Alzheimer's drugs may benefit whites more than Blacks
Reuters
Mon, 07/31/23 - 10:04 pm
Alzheimer's disease
racial disparity
After quitting FDA adcomm in protest of Aduhelm decision, Harvard's Aaron Kesselheim finds agency has an approval bias
Fierce Pharma
Mon, 07/31/23 - 10:07 am
FDA
Biogen
Aduhelm
Alzheimer's disease
advisory committees
drug approvals
I Was Concerned About Biogen Until I Heard These 11 Words From Its CEO
Motley Fool
Thu, 07/27/23 - 10:17 am
Biogen
Alzheimer's disease
Pharma CEOs
Chris Viehbacher
Companies to Watch: 12 Late-Stage Contenders in Neurodegenerative Disease
BioSpace
Mon, 07/24/23 - 09:57 am
neurodegenerative disease
Alzheimer's disease
Axsome Therapeutics
Eli Lilly
Anavex
TauRx
AB Science
ALS
BrainStorm Cell Therapeutics
Seelos Therapeutics
Parkinson's Disease
AbbVie
Mitsubishi Tanabe Pharma
Annovis
Huntington's disease
Prilenia Therapeutics
Neurocrine
After winning full FDA nod for Leqembi, Eisai touts 'promising' study on subcutaneous version
Fierce Pharma
Thu, 07/20/23 - 10:09 am
Eisai
Biogen
Leqembi
FDA
Alzheimer's disease
subcutaneous drug delivery
Lilly’s donanemab flaunts strong clinical profile, ready to compete with Leqembi
Clinical Trials Arena
Wed, 07/19/23 - 10:27 am
Eli Lilly
donanemab
Eisai
Biogen
Leqembi
Alzheimer's disease
AAIC 2023 – Acumen’s new amyloid approach impresses
EP Vantage
Wed, 07/19/23 - 10:15 am
AAIC
Acumen
Alzheimer's disease
ACU193
AAIC: First Clinical Data from an RNAi Therapeutic for Alzheimer’s Continue to Impress
BioSpace
Tue, 07/18/23 - 11:55 am
AAIC
Alnylam
RNAi
Alzheimer's disease
ALN-APP
clinical trials
Medicare’s Proposed Coverage for Alzheimer’s Scan Could Be Boon for Eisai/Biogen
BioSpace
Tue, 07/18/23 - 11:36 am
CMS
Alzheimer's disease
Eisai
Biogen
PET scans

Pages